NCT00002106View on ClinicalTrials.gov

A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3

PHASE2CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
DRUG

Ranitidine hydrochloride

Trial Locations (4)

27710

Duke Univ Med Ctr, Durham

33146

Community Research Initiative, Coral Gables

77006

Houston Clinical Research Network, Houston

91403

Pacific Oaks Med Group, Sherman Oaks

Sponsors

Lead Sponsor

Glaxo Wellcome
All Listed Sponsors
lead

Glaxo Wellcome

INDUSTRY

NCT00002106 - A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3 | Biotech Hunter | Biotech Hunter